AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-23423176_ITM" title="Facts and information about Cell Therapeutics' Ovarian Cancer Drug Xyotax Has Potential To Be The First Modified Taxane Launched In The Major Pharmaceutical Markets; Bristol-Myers Squibb and American Pharm Partners Also Have Modified Taxane Agents in Their Pipelines, According to a New Study from Decision Resources.">Cell Therapeutics' Ovarian Cancer Drug Xyotax Has Potential To Be The First Modified Taxane Launched In The Major Pharmaceutical Markets; Bristol-Myers Squibb and American Pharm Partners Also Have Modified Taxane Agents in Their Pipelines, According to a New Study from Decision Resources.</a>

Close Set up an RSS feed that alerts you when new articles from PR Newswire are available.

Frequently asked questions about RSS feeds

Cell Therapeutics' Ovarian Cancer Drug Xyotax Has Potential To Be The First Modified Taxane Launched In The Major Pharmaceutical Markets; Bristol-Myers Squibb and American Pharm Partners Also Have Modified Taxane Agents in Their Pipelines, According to a New Study from Decision Resources.

PR Newswire

| June 03, 2003 | COPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

WALTHAM, Mass. -- WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds Cell Therapeutics' ovarian cancer (CaO) drug Xyotax has the potential to be the first modified taxane to be launched in major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Xyotax is the only modified taxane to have reached Phase III development for CaO, making it most likely to achieve first-to-market status in this indication. However, according to the new Pharmacor study entitled Ovarian Cancer, the modified taxane pipeline is…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Avastin will be primary driver in ovarian cancer drug market, says Decision...: Newspaper article from: Pharma Marketletter October 31, 2005 700+ words
...new report from Decision Resources, a USA-based...market to treat ovarian cancer if data from the...platinum-refractory ovarian cancer, it says. DR...report, entitled Ovarian Cancer, finds that, pending...


Research and Markets: 20,180 New Cases of Ovarian Cancer will be Diagnosed this...: Press release article from: Business Wire August 2, 2006 700+ words
...announced the addition of the Decision Resources report: Emerging Diagnostic Biomarkers in Ovarian Cancer to their offering. Worldwide...before it metastasizes. In this Decision Resources report, we examine the pathophysiology...


Cell Therapeutics' ovarian cancer drug Xyotax has potential to be the first...: News wire article from: Asia Africa Intelligence Wire June 3, 2003 700+ words
...Business NewsBase - Press Release) Decision Resources Inc finds Cell Therapeutics' ovarian cancer (CaO) drug Xyotax has the potential...to the new Pharmacor study entitled Ovarian Cancer, the modified taxane pipeline is burgeoning...


Driven by Avastin, ovarian cancer market set to reach $1.6B by 2016.: Newspaper article from: Pharma Marketletter December 10, 2007 700+ words
...treatment of ovarian cancer will drive...advisory firm Decision Resources. The new...report, titled Ovarian Cancer, finds that...analyst at Decision Resources. "A cost...he added. Ovarian cancer is the leading...


Genentech/Roche's Avastin will be Primary Driver of Ovarian Cancer Drug Market...: Press release article from: PR Newswire October 25, 2005 700+ words
...PRNewswire/ -- Decision Resources, Inc., one...market to treat ovarian cancer if data from...analyst at Decision Resources, Inc. "Although...refractory ovarian cancer, clinicians...death in women. Ovarian cancer, often referred...Pharmacor from ...


Available Now: Target Product Profiles 2008: Physician Insights on Key...: Press release article from: M2 Presswire May 19, 2008 700+ words
...Key Attributes - Ovarian Cancer (Advanced Stage...addition of the new Decision Resources Inc. report "Target...Key Attributes - Ovarian Cancer (Advanced Stage...treatment of advanced ovarian cancer. Using Target Product...


Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages...: Press release article from: PR Newswire April 23, 2008 700+ words
...Jenna Avent, analyst at Decision Resources. "However, the regimen...treatment of advanced ovarian cancer." About the Report Ovarian Cancer (Advanced): Therapies...DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines...


Driven By Genentech/Roche/Chugai's Avastin, the Ovarian Cancer Drug Market Will...: Press release article from: PR Newswire December 3, 2007 700+ words
...PRNewswire/ -- Decision Resources, one of the...treatment of ovarian cancer will drive...mortality rate of ovarian cancer will continue...analyst at Decision Resources. "A cost...About Ovarian Cancer Ovarian cancer...


Ovarian cancer strikes one in 68 women: Now experts agree on a set of symptoms...: Newspaper article from: Tulsa World (Tulsa, OK) August 2, 2007 700+ words
...estimated 15,000 Americans die of ovarian cancer, where malignant cells are found in...organs, the ovaries. For a long time, ovarian cancer was called the "silent killer" because...poor. Almost 70 percent of women with ovarian cancer are not diagnosed until the disease...


Ovarian cancer, a silent killer for Indonesian women: Study.: Newspaper article from: Jakarta Post August 9, 2000 700+ words
...may be at a high risk of developing ovarian cancer. Dr. Sjahrul Sjamsuddin, a gynecologist...said the doctor during a seminar on ovarian cancer. Only a very few realize that the...talcum powder and the development of ovarian cancer in women," he said. The doctor explained...

For more facts and information, see all results

Source: HighBeam Research, Cell Therapeutics' Ovarian Cancer Drug Xyotax Has Potential To Be The...

The AccessMyLibrary advertising network includes: